8-K: Graphite Bio Stockholders Approve Merger with LENZ Therapeutics and Related Proposals

Graphite Bio stockholders have approved the merger with LENZ Therapeutics, along with related proposals including a reverse stock split and a name change to LENZ Therapeutics, Inc.

Summary

• Graphite Bio held a special meeting on March 14, 2024, where stockholders voted on proposals related to the merger with LENZ Therapeutics.
• The stockholders approved the issuance of Graphite common stock to LENZ stockholders, representing more than 20% of outstanding shares, and the change of control resulting from the merger.
• A reverse stock split, with a ratio between 1:6 and 1:12, was approved, along with a name change to LENZ Therapeutics, Inc.
• The 2024 Equity Incentive Plan and the 2024 Employee Stock Purchase Plan, both contingent on the merger's completion, were also approved.
• A total of 48,498,051 shares were represented at the meeting, out of 58,230,156 shares outstanding, establishing a quorum.

Sentiment

Score: 7

Explanation: The document reflects a positive outcome with the approval of the merger and related proposals, but also includes standard risk disclosures, resulting in a moderately positive sentiment.

Positives

• The merger with LENZ Therapeutics has been approved by Graphite Bio stockholders.
• All proposals related to the merger, including the reverse stock split and name change, were approved.
• The approval of the 2024 Equity Incentive Plan and Employee Stock Purchase Plan sets the stage for the combined company's future operations.
• A quorum was achieved at the special meeting, indicating strong shareholder participation.

Risks

• The merger is subject to the satisfaction or waiver of conditions set forth in the Merger Agreement.
• The actual results of the combined company could differ materially from forward-looking statements due to various risks and uncertainties.
• There is a risk that the conditions to the closing of the merger are not satisfied.

Future Outlook

The document includes forward-looking statements regarding the structure, timing, and completion of the merger, the combined company's listing on Nasdaq, its cash position, future operations, and clinical development activities. These statements are subject to risks and uncertainties.

Management Comments

• Kim Drapkin, President and Interim Chief Executive Officer, signed the report on behalf of Graphite Bio.

Industry Context

This merger is part of a trend in the biotech industry where companies combine to leverage resources, pipelines, and expertise. The merger will allow the combined entity to pursue a broader range of therapeutic opportunities.

Comparison to Industry Standards

• Mergers and acquisitions are common in the biotech industry, often driven by the need to consolidate resources and pipelines.
• The reverse stock split is a common mechanism used to maintain listing compliance on exchanges like Nasdaq.
• The approval of equity incentive plans and employee stock purchase plans is standard practice for companies to attract and retain talent.

Stakeholder Impact

• Shareholders of Graphite Bio have approved the merger, which will result in a change of ownership and a new company name.
• Employees of both Graphite Bio and LENZ Therapeutics will be impacted by the merger, with new equity incentive and stock purchase plans in place.
• The merger is expected to create a combined entity with a broader range of therapeutic opportunities, potentially benefiting patients and the healthcare industry.

Next Steps

• The merger between Graphite Bio and LENZ Therapeutics is expected to be completed.
• The combined company will operate under the name LENZ Therapeutics, Inc.
• The reverse stock split will be implemented at a ratio between 1:6 and 1:12.
• The 2024 Equity Incentive Plan and Employee Stock Purchase Plan will become effective upon completion of the merger.

Key Dates

Keywords

Merger, Graphite Bio, LENZ Therapeutics, Stockholder Vote, Reverse Stock Split, Name Change, Equity Incentive Plan, Employee Stock Purchase Plan